Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and.

Slides:

Advertisements

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Joshua E. Rosen, BASc, Hari B

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel,

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Electronic Updates for JTO Readers

A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) Primo N. Lara,

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer Rogerio.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated.

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation.

It’s All in the “Swerve of the Curve”

A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Is Pneumonectomy After Induction Chemotherapy for Non-small Cell Lung Cancer a Reasonable Procedure? A Multicenter Retrospective Study of 228 Cases Yoann.

RTOG 0017: A Phase I Trial of Concurrent Gemcitabine/Carboplatin or Gemcitabine/Paclitaxel and Radiation Therapy (“Ping-Pong Trial”) Followed By Adjuvant.

High Frequency of Radiation Pneumonitis in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Concurrent Radiotherapy and Gemcitabine.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer:

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

International Thymic Malignancies Interest Group: A Way Forward

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer:

Induction Therapy For Locally Advanced Thymoma

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

A Review of First-Line Treatment for Small-cell Lung Cancer

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage.

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer Vera Hirsh, MD, Denis Soulieres, MD, Marie Duclos, MD, Sergio Faria, MD, Pierre Del Vecchio, MD, Linda Ofiara, MD, Jean-Pierre Ayoub, MD, Danielle Charpentier, MD, James Gruber, MD, Lorraine Portelance, MD, Luis Souhami, MD Journal of Thoracic Oncology Volume 2, Issue 10, Pages 927-932 (October 2007) DOI: 10.1097/JTO.0b013e3181560b92 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan-Meier survival distribution curve including all assessable patients. Journal of Thoracic Oncology 2007 2, 927-932DOI: (10.1097/JTO.0b013e3181560b92) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions